Gentamicin Sulfate

Inflammation, Ecthyma, Eczema + 36 more
Treatment
11 FDA approvals
20 Active Studies for Gentamicin Sulfate

What is Gentamicin Sulfate

GentamicinThe Generic name of this drug
Treatment SummaryGentamicin is an antibiotic used to treat serious bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa. When taken in combination with other antibiotics, it can be more effective and cause fewer side effects. However, gentamicin can cause serious adverse effects, including kidney and hearing damage, which may limit its use.
Gentamicinis the brand name
image of different drug pills on a surface
Gentamicin Sulfate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Gentamicin
Gentamicin
1982
125

Approved as Treatment by the FDA

Gentamicin, also called Gentamicin, is approved by the FDA for 11 uses including Communicable Diseases and severe Infection Pseudomonas aeruginosa .
Communicable Diseases
Used to treat Susceptible infections in combination with Betamethasone
severe Infection Pseudomonas aeruginosa
Used to treat severe Infection Pseudomonas aeruginosa in combination with Carbenicillin
severe Endocarditis enterococcal
Used to treat severe Endocarditis enterococcal in combination with Benzylpenicillin
Inflammation
Used to treat Inflammation in combination with Betamethasone
Bacterial Infections
Skin Infections
Used to treat Skin Infections in combination with Betamethasone
Inflammation
Used to treat Inflammation in combination with Betamethasone
Communicable Diseases
Used to treat severe Infection Pseudomonas aeruginosa in combination with Carbenicillin
Communicable Diseases
Used to treat Skin Infections in combination with Betamethasone
Endocarditis
Used to treat severe Endocarditis enterococcal in combination with Benzylpenicillin
Urinary Tract Infection (UTI)

Effectiveness

How Gentamicin Sulfate works in the bodyAminoglycosides work in three stages to fight bacteria. First, the drugs bind to the outer cell membrane, which increases the cell's permeability. Then, they are able to enter the cytoplasm and target the 30S ribosome, which is responsible for protein synthesis. Finally, they cause damage to the cytoplasmic membrane and block protein synthesis, leading to bacterial death. The drugs require oxygen-dependent active transport to be effective, which is why they are not effective against anaerobic bacteria.

When to interrupt dosage

The prescribed amount of Gentamicin Sulfate is contingent upon the determined disorder, such as Blepharitis, Corneal contagion and Dermatitis infected. The measure of dosage changes as per the method of delivery (e.g. Intravenous or Liquid - Ophthalmic; Topical) delineated in the table below.
Condition
Dosage
Administration
Blepharoconjunctivitis
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Pustular acne
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Skin Diseases
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
ocular bacterial infections
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Impetigo contagious
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Keratoconjunctivitis
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Endocarditis
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Bacterial Infections
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Urinary Tract Infections
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Conjunctivitis, Bacterial
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Conjunctivitis
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Communicable Diseases
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Inflammation
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Eczema
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Pyoderma Gangrenosum
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Corneal infection
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Dacryocystitis
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Meibomianitis
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Sycosis barbae
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops
Sycosis
0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg
, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Solution - Ophthalmic, Ointment - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Solution - Auricular (otic), Liquid, Liquid - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Parenteral, Implant - Parenteral, Implant, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Warnings

Gentamicin Sulfate Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Gentamicin may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Gentamicin may interact with Pulse Frequency
There are 20 known major drug interactions with Gentamicin Sulfate.
Common Gentamicin Sulfate Drug Interactions
Drug Name
Risk Level
Description
Agalsidase beta
Major
The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Gentamicin is combined with Neomycin.
Tenofovir
Major
Gentamicin may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Gentamicin may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir disoproxil
Major
Gentamicin may increase the nephrotoxic activities of Tenofovir disoproxil.
Gentamicin Sulfate Toxicity & Overdose RiskGentamicin is an aminoglycoside that can cause kidney or hearing damage. Signs of kidney damage include elevated creatinine and urea levels, while signs of hearing damage include balance problems, ringing in the ears, nausea, and hearing loss. Long-term use increases the risk of toxicity, but it is difficult to predict when hearing damage will occur. If gentamicin toxicity or overdose is suspected, the medication should be stopped right away and dialysis may be used to reduce gentamicin levels in the blood.
image of a doctor in a lab doing drug, clinical research

Gentamicin Sulfate Novel Uses: Which Conditions Have a Clinical Trial Featuring Gentamicin Sulfate?

219 active clinical trials are exploring the possibility of Gentamicin Sulfate to reduce Inflammation, Ocular Inflammation and Allergic Conjunctivitis (AC).
Condition
Clinical Trials
Trial Phases
Inflammation
58 Actively Recruiting
Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4
Bacterial Infections
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Keratitis
0 Actively Recruiting
Sycosis barbae
0 Actively Recruiting
Blepharoconjunctivitis
0 Actively Recruiting
Keratoconjunctivitis
0 Actively Recruiting
Pustular Psoriasis (PP)
0 Actively Recruiting
Ecthyma
0 Actively Recruiting
Impetigo contagious
0 Actively Recruiting
ocular bacterial infections
0 Actively Recruiting
Dacryocystitis
0 Actively Recruiting
Staphylococcal Infections
0 Actively Recruiting
Urinary Tract Infections
0 Actively Recruiting
Bacterial Peritonitis
0 Actively Recruiting
Pyoderma Gangrenosum
2 Actively Recruiting
Phase 2, Phase 3
Pustular acne
0 Actively Recruiting
Endocarditis
0 Actively Recruiting
Allergic Conjunctivitis (AC)
1 Actively Recruiting
Phase 2
Sycosis
0 Actively Recruiting

Gentamicin Sulfate Reviews: What are patients saying about Gentamicin Sulfate?

2.3Patient Review
2/10/2009
Gentamicin Sulfate for Multiple Drugs for Skin Infection due to Pseudomonas Aeruginosa Bacteria
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about gentamicin sulfate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is gentamicin sulfate cream an antibiotic?

"Gentamicin Sulfate is an effective antibiotic for primary and secondary bacterial skin infections. It may be used for infections that have not responded to other topical antibiotics."

Answered by AI

What is gentamicin sulfate used for?

"This medication is used to treat minor skin infections, such as impetigo and folliculitis, or minor infections related to some skin conditions, such as eczema and psoriasis. Gentamicin works by stopping the growth of certain bacteria."

Answered by AI

Is gentamicin a strong antibiotic?

"Gentamicin is a type of antibiotic that is effective against gram-negative rods. It can also be used in combination with other antibiotics to treat infections caused by gram-positive organisms."

Answered by AI

What diseases does gentamicin treat?

"Gentamicin Injection is used to treat certain serious infections including meningitis, infection of the blood, abdomen, lungs, skin, bones, joints, and urinary tract."

Answered by AI

Clinical Trials for Gentamicin Sulfate

Image of UConn Health in Farmington, United States.

Cognitive Remediation for Memory and Thinking Difficulties

18+
All Sexes
Farmington, CT
The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation ("brain training") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are: * Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction? * Will treatment effects be maintained over time, leading to better long term cognitive outcomes? * Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement? * Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction. Participation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including: * Initial intake visit: Eligibility confirmation (\~2-3 hours) * Computer activities: About 5 hours per week for \~6 weeks (total \~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase * Weekly remote check-in meetings: \~30 minutes each during treatment * Blood draws: Two sessions (before and after treatment), \~20-30 minutes each * Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)
Waitlist Available
Has No Placebo
UConn HealthCutter Lindbergh, Ph.D.
Have you considered Gentamicin Sulfate clinical trials? We made a collection of clinical trials featuring Gentamicin Sulfate, we think they might fit your search criteria.Go to Trials
Image of Department of Nutritional Sciences in Storrs, United States.

Freeze-dried Grape Powder for Healthy Aging

50 - 75
All Sexes
Storrs, CT
The purpose of this study is to investigate the effects of consuming grape powder on immune profiles in healthy middle- and older-aged individuals. Specifically, the investigators are interested in evaluating the potential effects of grapes in influencing markers of immune function, inflammation, and metabolism that are known to change with aging. Grapes contain several nutrients and antioxidant polyphenols such as resveratrol, quercetin, vitamin K and fiber, which are known to promote heart and immune health. However, the effects of grapes on altering immune profiles within the context of aging is not well understood. Therefore, this study will explore how daily grape consumption impacts certain markers of immunity in healthy middle- and older-aged adults. The main study procedures include consumption of a freeze-dried grape powder and control powder (which tastes the same but has none of the grape compounds that are being studied) mixed with water as a beverage on a daily basis for 4 weeks each. The investigators will additionally ask that participants avoid eating grapes and certain other antioxidant/grape-related foods and beverages throughout the 13-week study. Participants will additionally be asked to complete surveys about their diet, physical activity, and medical history, as well as provide blood samples and body weight measures throughout the course of the study. Participation in the study is expected to last about 6.25 hours over the course of 13 weeks and will include 7 visits.
Recruiting
Paid Trial
Department of Nutritional Sciences
Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Phase 2
Recruiting
Abcentra Investigational Site (+6 Sites)Abcentra
Image of School of Public Health in Bloomington, United States.

High Salt Intake for High Blood Pressure

60 - 85
All Sexes
Bloomington, IN
Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury/impaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.
Recruiting
Has No Placebo
School of Public Health
Have you considered Gentamicin Sulfate clinical trials? We made a collection of clinical trials featuring Gentamicin Sulfate, we think they might fit your search criteria.Go to Trials
Image of Goldring Center for High Performance Sport in Toronto, Canada.

Physical Activity for Delayed Onset Muscle Soreness

18 - 35
All Sexes
Toronto, Canada
After completing novel activity or exercise we may experience exercise-induced muscle damage (EIMD), resulting in a period of reduced muscle function and delayed onset muscle soreness (DOMS). DOMS is characterized by muscle pain and tenderness that typically resolves within a week. While the precise cause of DOMS is unknown, there is growing evidence implicating damage to the connective tissue that surrounds our muscle fibers and is related to a small amount of inflammation. This inflammation is a normal part of our body's ability to recovery from injuries and may be visualized through the use of ultrasound technology. A variety of recovery techniques have been proposed that may help with the recovery of DOMS such as massage and electrical muscle stimulation, but these are not always accessible. Therefore, we are interested in investigating whether the number of daily steps can affect how you experience DOMS.
Waitlist Available
Has No Placebo
Goldring Center for High Performance Sport
Image of UCSF in San Francisco, United States.

Moisturizers for Aging

65+
All Sexes
San Francisco, CA
This is a randomized, investigator-blinded, self-controlled pilot study of the physiologic response to topical moisturizers among older adults with dry skin. The overarching hypothesis is that skin barrier decline is an important source of chronic inflammation, and that skin barrier restoration with moisturizers can reduce serum biomarkers of inflammation. The primary objective is to determine the feasibility for a larger trial, and the secondary objectives are to determine the extent to which measures of serum inflammation, skin barrier function, and the skin microbiome change in response to moisturizers. Participants will be asked to apply one of two topical moisturizers that are widely available over the counter in the US (Vaseline® 100% pure petroleum jelly or CeraVe® moisturizing cream) once daily for 4 weeks to the front of the torso, buttocks, arms, and legs. Subjects will act as their own control (i.e. they will be asked to apply the study moisturizer they are randomized to for one intervention period (4 weeks) and not to apply topical moisturizers for the other 4- week intervention period). Participants will be randomized in a 1:1:1:1 ratio to one of 4 treatment groups: i. no intervention then CeraVe; ii. CeraVe then no intervention; iii. no intervention then Vaseline; iv. Vaseline then no intervention. At each visit (baseline, week 4, and week 8), participants will undergo skin barrier testing, skin microbiome sampling, and phlebotomy to measure serum inflammatory markers.
Phase 4
Recruiting
UCSFKatrina Abuabara, MD
Have you considered Gentamicin Sulfate clinical trials? We made a collection of clinical trials featuring Gentamicin Sulfate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security